Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology

Author:

Spaan Mandy1ORCID,van den Belt-Dusebout Alexandra W1ORCID,Lambalk Cornelis B2ORCID,van Boven Hester H3,Schats Roel2,Kortman Marian4,Broekmans Frank J M4,Laven Joop S E5,van Santbrink Evert J P6ORCID,Braat Didi D M7,van der Westerlaken Lucette A J8,Cohlen Ben J9,Cantineau Astrid E P10,Smeenk Jesper M J11,van Rumste Minouche M12,Goddijn Mariëtte13ORCID,van Golde Ron J T14,Meeuwissen Paul A M15,Hamilton Carl J C M16,Ouwens Gabriële M1,Gerritsma Miranda A1,Schaapveld Michael1,Burger Curt W5,van Leeuwen Flora E1ORCID

Affiliation:

1. Department of Epidemiology, Netherlands Cancer Institute, Amsterdam, the Netherlands

2. Department of Obstetrics & Gynecology, Amsterdam University Medical Center (UMC) Location, VU University Medical Center, Amsterdam, the Netherlands

3. Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands

4. Department of Reproductive Medicine and Gynecology, University Medical Center Utrecht, Utrecht, the Netherlands

5. Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Erasmus Medical Center, Rotterdam, the Netherlands

6. Department of Reproductive Medicine, Reinier de Graaf Hospital, Voorburg, the Netherlands

7. Department of Obstetrics and Gynecology, Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands

8. Department of Obstetrics, Gynecology and Reproductive Medicine, Leiden University Medical Center, Leiden, the Netherlands

9. Department of Obstetrics and Gynecology, Isala Clinics, Zwolle, the Netherlands

10. Department of Obstetrics and Gynecology, University Medical Center Groningen, University Groningen, Groningen, the Netherlands

11. Department of Obstetrics and Gynecology, St Elisabeth Hospital, Tilburg, the Netherlands

12. Department of Obstetrics and Gynecology, Catharina Hospital, Eindhoven, the Netherlands

13. Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Amsterdam UMC Location, Academic Medical Center, Amsterdam, the Netherlands

14. Department of Obstetrics and Gynecology, Maastricht University Medical Center, Maastricht, the Netherlands

15. Department of Obstetrics and Gynecology, Admiraal de Ruyter Hospital, Vlissingen, the Netherlands

16. Department of Obstetrics and Gynecology, Jeroen Bosch Ziekenhuis, ‘s-Hertogenbosch, the Netherlands

Abstract

Abstract Background Long-term effects of assisted reproductive technology (ART) on ovarian tumor risk are unknown. Methods This nationwide cohort study comprises 30 625 women who received ovarian stimulation for ART in 1983-2000 and 9988 subfertile women not treated with ART. Incident invasive and borderline ovarian tumors were ascertained through linkage with the Netherlands Cancer Registry and the Dutch Pathology Registry until July 2018. Ovarian tumor risk in ART-treated women was compared with risks in the general population and the subfertile non-ART group. Statistical tests were 2-sided. Results After a median follow-up of 24 years, 158 invasive and 100 borderline ovarian tumors were observed. Ovarian cancer risk in the ART group was increased compared with the general population (standardized incidence ratio [SIR] = 1.43, 95% confidence interval [CI] = 1.18 to 1.71) but not when compared with the non-ART group (age- and parity-adjusted hazard ratio [HR] = 1.02, 95% CI = 0.70 to 1.50). Risk decreased with higher parity and with a larger number of successful ART cycles (resulting in childbirth, Ptrend = .001) but was not associated with the number of unsuccessful ART cycles. Borderline ovarian tumor risk was increased in ART-treated women compared with the general population (SIR = 2.20, 95% CI = 1.66 to 2.86) and with non-ART women (HR = 1.84, 95% CI = 1.08 to 3.14). Risk did not increase with more ART cycles or longer follow-up time. Conclusions Increased ovarian cancer risk in ART-treated women compared with the general population is likely explained by nulliparity rather than ART treatment. The increased risk of borderline ovarian tumors after ART must be interpreted with caution because no dose-response relationship was observed.

Funder

Dutch Cancer Society

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Reference22 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3